Recent Advances in the Treatment of Advanced HER2+ Breast Cancer: SABCS 2024 - Episode 6
Proactive AE Management and Prophylactic Strategies With TADCs in Breast Cancer
Panelists discuss how trastuzumab deruxtecan’s (T-DXd's) key adverse events (AEs) include interstitial lung disease, neutropenia, and nausea/fatigue, emphasizing the importance of proactive monitoring, early intervention through coordinated multidisciplinary care, and comprehensive patient education with clear communication channels for reporting symptoms.
Video Player is loading.
Video content above is prompted by the following:
- What treatment-related AEs do you observe in patients receiving T-DXd, and which are the most challenging to manage?
- How do you coordinate care with the multidisciplinary team, and what strategies do you implement to optimize the management of these AEs?
- How do you educate patients about potential AEs, and what resources do you provide for support?